Everything You Need to Know About Tirzepatide for Weight Management
Mounjaro has become one of the most talked-about weight management medicines in the UK. It works differently from other GLP-1 treatments, and the clinical results are among the strongest seen in any weight management medication to date. Here’s what it is, how it works, and what to realistically expect.
Key Takeaways
- Mounjaro (tirzepatide) is a prescription-only dual-hormone weight management injection, licensed by the MHRA for adults with a BMI of 30 or above, or 27 or above with a weight-related health condition
- It acts on two hormone pathways simultaneously, which may explain its stronger results compared to single-hormone treatments
- In the SURMOUNT-1 trial, participants at the highest dose lost an average of 20.9% of their body weight over 72 weeks¹
- It’s available privately in the UK through clinician-led services, including Weightfall, and requires a prescription following a clinical assessment
- Mounjaro works best as part of a supervised programme that includes lifestyle support
What Is Mounjaro?
Mounjaro is the brand name for tirzepatide, a medicine developed by Eli Lilly. It’s given as a once-weekly subcutaneous injection, available in doses from 2.5mg up to 15mg, and the dose gradually increases over time as the body adjusts.
It was approved by the MHRA for weight management in the UK in 2023 and received NICE approval for NHS use in 2024.² NHS access remains limited and prioritised for those with the highest clinical need, which is why most people in the UK currently access it privately through services like Weightfall.
Mounjaro is not the same as Ozempic or Wegovy, though all three affect appetite regulation. Mounjaro acts on two hormone receptors rather than one, which is the key distinction.
How Does Mounjaro Work?
Most weight management injections are GLP-1 receptor agonists. They mimic one gut hormone to reduce appetite. Mounjaro is different. It acts on both GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide) receptors simultaneously.¹
GLP-1 slows gastric emptying, reduces appetite, and helps regulate blood sugar. GIP plays a role in fat metabolism and also contributes to satiety. By activating both pathways together, tirzepatide produces a broader and often stronger metabolic effect than GLP-1 alone.
The result is meaningful reduction in appetite, improved blood sugar regulation, and, in clinical trials, greater average weight loss than with single-hormone treatments.
What the Clinical Evidence Shows
- The SURMOUNT programme is the primary clinical evidence base for Mounjaro. In SURMOUNT-1, which followed adults with a higher body weight but without type 2 diabetes, participants taking 15mg of tirzepatide lost an average of 20.9% of their body weight over 72 weeks.¹ More than half of the participants in the 10mg and 15mg groups lost at least 20% of their starting weight.
- SURMOUNT-4 showed something equally important: stopping treatment led to significant weight regain within a year.³ This reinforces that Mounjaro works best as a long-term component of a managed programme, not a short course.
Who Can Get a Mounjaro Prescription?
To receive a Mounjaro prescription in the UK, you need to meet clinical eligibility criteria. The MHRA-licensed thresholds are a BMI of 30 or above, or a BMI of 27 or above with at least one weight-related health condition such as high blood pressure, raised cholesterol, or type 2 diabetes.²
Mounjaro is not appropriate for everyone. A clinician will review your full medical history before prescribing, including any medications you’re taking and any relevant conditions.
Does Mounjaro Require a Special Diet?
There’s no specific “Mounjaro diet.” The medication reduces appetite, which naturally makes it easier to eat less. What works best alongside it is a balanced, protein-rich approach to eating, because tirzepatide helps preserve muscle mass, but adequate protein intake supports that process.³
Avoiding high-fat meals, particularly early in treatment, can help manage gastrointestinal side effects like nausea. Regular meals rather than skipping and then overeating will also improve how you feel during the dose escalation phase.
If you want to find out if Mounjaro is right for you, you can explore Weightfall’s 2 way receptor programme and check your eligibility.
Frequently Asked Questions
What is Mounjaro, and how does it work?
Mounjaro is a prescription weekly injection containing tirzepatide. Unlike most weight management medications, it acts on two gut hormone receptors (GLP-1 and GIP) simultaneously. This dual mechanism reduces appetite, slows digestion, and helps regulate blood sugar, supporting meaningful weight loss when combined with lifestyle changes.
What is the BMI for Mounjaro eligibility?
The MHRA-licensed threshold for Mounjaro is a BMI of 30 or above, or a BMI of 27 or above with at least one weight-related health condition. People from certain ethnic backgrounds may qualify at a lower BMI due to a higher health risk at lower BMI values.
Does Mounjaro require a prescription?
Yes. Mounjaro is a prescription-only medicine in the UK. It cannot be purchased over the counter. Any legitimate provider will require you to complete a clinical assessment before a prescriber considers whether treatment is appropriate.
Is Mounjaro available on the NHS?
Mounjaro received NICE approval for NHS use in 2024. However, NHS access is currently limited and reserved for those with the highest clinical need. Most people in the UK currently access it privately through clinician-led weight management services.
How is Mounjaro given?
Mounjaro is given as a once-weekly injection under the skin, using a pre-filled pen. Common injection sites are the abdomen, thigh, or upper arm. The dose starts at 2.5mg and is increased gradually every four weeks, up to a maximum of 15mg, as tolerated.
What foods should I avoid on Mounjaro?
There’s no strict exclusion list, but high-fat, high-calorie meals can worsen nausea during the early weeks of treatment. Most people find that smaller, regular meals with adequate protein help them feel better and support better results. Your Weightfall clinician can offer personalised guidance.
How quickly does Mounjaro work?
Appetite changes are often noticed within the first week or two. Measurable weight loss typically begins within four to eight weeks. In clinical trials, the most significant results were seen progressively over 12 to 72 weeks.
Read more: How Long Does Wegovy Take to Work?
References
[1] Jastreboff AM, et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). N Engl J Med. 2022;387(3):205-216. https://doi.org/10.1056/NEJMoa2206038
[2] National Institute for Health and Care Excellence (NICE). Tirzepatide for managing overweight and obesity (TA1026). 2024. Available at: https://www.nice.org.uk/guidance/ta1026
[3] Aronne LJ, et al. Continued treatment with tirzepatide for maintenance of weight reduction in adults with obesity (SURMOUNT-4). JAMA. 2024;331(1):38-48. https://doi.org/10.1001/jama.2023.24945